09 July 2026 : Clinical Research
Preliminary Application of Antihypertensive Gene Detection in the Treatment of Hypertension
Dongde Xie ABCDEFG 1*, Mingming Deng ABCDEFG 1, Xiaoming Yang ABCDEFG 1, Jie Huang ABCDEFG 1, Xucan Hong ABCDEFG 1, Ning Xu ABCDEFG 1DOI: 10.12659/MSM.952296
Med Sci Monit 2026; 32:e952296
Table 1 Genotype and allele frequencies of the 6 pharmacogenomic loci in the study group (n=450).
| Gene (polymorphism) | Genotype | Number of patients (n) | Genotype frequency (%) | Allele | Allele frequency (%) | Notes/phenotype implication |
|---|---|---|---|---|---|---|
| CYP2D6 (*10) | *10/*10 | 120 | 26.7% | *10 | 51.1% | Reduced metabolizer |
| *1/*10 | 180 | 40.0% | *1 | 48.9% | ||
| *1/*1 | 150 | 33.3% | Normal metabolizer | |||
| CYP2C9 (*3) | *1/*1 | 380 | 84.4% | *1 | 91.8% | Normal metabolizer |
| *1/*3 | 65 | 14.4% | *3 | 8.2% | Reduced metabolizer | |
| *3/*3 | 5 | 1.1% | Poor metabolizer | |||
| AGTR1 (A1166C) | AA | 260 | 57.8% | A | 75.6% | Reference allele |
| AC | 160 | 35.6% | C | 24.4% | Associated with drug response | |
| CC | 30 | 6.7% | ||||
| ACE (I/D) | II | 110 | 24.4% | I | 48.9% | Lower ACE activity |
| ID | 220 | 48.9% | D | 51.1% | Higher ACE activity | |
| DD | 120 | 26.7% | ||||
| NPPA (T2238C) | TT | 300 | 66.7% | T | 81.1% | Reference allele |
| TC | 125 | 27.8% | C | 18.9% | Linked to diuretic response | |
| CC | 25 | 5.6% | ||||
| CYP3A5 (*3) | *1/*1 | 70 | 15.6% | *1 | 34.4% | Normal metabolizer |
| *1/*3 | 200 | 44.4% | *3 | 65.6% | Reduced metabolizer | |
| *3/*3 | 180 | 40.0% | Poor metabolizer | |||
| Genotype and allele distribution of the 6 pharmacogenomic variants in the study group (n=450). Frequencies are expressed as percentages. | ||||||